Loading…
Please register to continue your trial period!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
The majority (80–85%) of lung cancer cases are non-small-cell cancer (NSCLC) (American Cancer Society. Lung cancer (non-small cell) (2020)), with approximately 50% of patients with Non-small-cell lung carcinoma (NSCLC) being diagnosed in the nonmetastatic setting (Cancer stat facts: lung and bronchus cancer. https://seer.cancer.gov/statfacts/html/lungb.html) and an estimated 20–25% being candidates for surgery
Although early-stage non–small cell lung cancer (NSCLC) is potentially curable, patients with stage IB-IIIA NSCLC have a very high risk of recurrence and suboptimal survival. The 5-year overall survival rate ranges from 24% to 58% in patients with stage IIIA and IB NSCLC, respectively.
However, the prognosis remains poor, with a 5…